Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (NCT02486718)
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group — Fayetteville, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (155 Sites)
Showing the first 25 of 155 sites.
- Highlands Oncology Group — Fayetteville, Arkansas
- California Cancer Associates for Research & Excellence, Inc. — Encinitas, California
- Compassionate Cancer Care Medical Group, Inc — Fountain Valley, California
- University of California Los Angeles — Los Angeles, California
- Kaiser Permanente — Vallejo, California
- Kaiser Permanente - Walnut Creek — Walnut Creek, California
- Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut
- Lynn Cancer Institute - West — Boca Raton, Florida
- University of Miami School of Medicine - Sylvester at Deerfield — Deerfield Beach, Florida
- SCRI Florida Cancer Specialists North — St. Petersburg, Florida
- Lewis Hall Singletary Oncology Center — Thomasville, Georgia
- University of Illinois at Chicago — Chicago, Illinois
- Illinois Cancer Care — Peoria, Illinois
- Norton Cancer Institute — Louisville, Kentucky
- St. Luke's Cancer Institute — Kansas City, Missouri
- Hematology Oncology Associates of Northern New Jersey — Florham Park, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Valley Hospital — Paramus, New Jersey
- Overlook Medical Center — Summit, New Jersey
- Clinical Research Alliance — Lake Success, New York
- Weill Cornell Medical College — New York, New York
- Presbyterian Hospital — Charlotte, North Carolina
- University of Cincinnati — Cincinnati, Ohio
- Oncology Hematology Care - SCRI — Cincinnati, Ohio
- Oregon Health and Science University — Portland, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.